Moderna Stock No-Brainer After FDA Win: Buy or Not?
A recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
Identify the mix that offers broader exposure for retirement by comparing Sp500 and total market allocations and adjusting for risk.
28,595 articlesA recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
Soleno's Q4 2025 earnings paint a picture of growth with new products and expanding margins. This guide breaks down t...
L’Oréal’s innovation chief says speed isn’t enough in AI-driven markets; enduring success comes from history, structu...
A leading hedge fund shocks markets with a major pivot into AI infrastructure, prioritizing hardware, energy-ready da...
A landmark joint interpretive guidance from the SEC and CFTC clarifies crypto regulation, focusing on security classi...
The VIX surges about 10% as Brent breaches the $100 mark, signaling rising fear among traders and a shift toward risk...
Elon Musk’s clash with OpenAI doubles as a bid to launch xAI, with Tesla financing and strategic partnerships setting...
As GM speeds toward a broader electric-vehicle lineup, Mary Barra keeps a centuries-old habit: replying to every lett...
Goldman Sachs warns that China's oil demand may not return to its pre-crisis trajectory, highlighting a potential, la...
Tilray Brands is targeting a milestone $1.2 billion in annual revenue next year. This article digs into how the compa...
Trump argues against rate hikes amid a stubborn inflation backdrop, while Kevin Warsh appears set to influence a hawk...
Bitcoin sits near $63,000 as a familiar 91-day cycle returns to the spotlight. Traders say the bitcoin price predicti...